Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (April 29th Preview)
-
Regulators move to accelerate clinical trial oversight using real-time data and AI
The FDA announced a pilot approach to review clinical trial data in real time, starting with datasets from AstraZeneca and Amgen. The agency said it will also solicit feedback on a potential program for companies using AI to support safety monitoring, dose selection, safety signal detection, and patient recruitment. A central element is the real-time data platform Paradigm Health is building for the pilot trials, according to the FDA. The Phase 2 AstraZeneca study of an aggressive lymphoma regimen will run at MD Anderson and the University of Pennsylvania, while Amgen’s Phase 1b small-cell lung cancer trial will use the same real-time reporting concept. If adopted broadly, the initiative could shorten the information latency between trial events and regulator review, reshaping how sponsors design data flows and monitoring systems for pivotal studies.
-
FDA pulls Tavneos approval, citing manipulated trial data
The FDA moved to withdraw Amgen’s Tavneos (avacopan) after alleging that information used to support approval included untrue statements of material fact and that trial results were manipulated. The action adds to mounting scrutiny on the underlying evidence package that supported the 2022 buyout of Chemocentryx for $3.7 billion. Separately, the reporting describes the FDA’s concern that the developer concealed analysis and altered data, escalating the agency’s attempt to remove the therapy from the market. Amgen has disputed the decision, refusing to voluntarily withdraw and maintaining the product is safe. For sponsors and CROs, the case raises the operational risk around data handling, analysis transparency, and documentation practices across pivotal programs.
-
Obesity drug pipeline steps forward in Phase 3 with Boehringer’s survodutide
Boehringer Ingelheim reported Phase 3 topline results for survodutide, its dual-acting obesity drug that targets GLP-1 and glucagon. In the Synchronize-1 trial of 725 participants, the company said weight loss was significantly greater than placebo and that treatment appeared to help preserve muscle mass. Boehringer licensed survodutide from Zealand Pharma. Wall Street commentary in the reporting described the weight loss profile as comparable to Wegovy but below Zepbound, while analysts awaited more detail on side effects and additional data in a liver disease (MASH) study. The Phase 3 readout extends the competitive pressure in obesity pharmacotherapy where lean-mass preservation has become a differentiator alongside percent weight loss.
-
Precision oncology diagnostics: CareDx to acquire Naveris for NavDx and HPV MRD access
CareDx agreed to buy Naveris in a deal valued at up to $260 million, including $160 million upfront and as much as $100 million tied to revenue milestones. The acquisition is designed to expand CareDx’s precision oncology footprint through Naveris’ liquid biopsy test NavDx, which monitors HPV-related cancers by measuring circulating viral DNA fragments. CareDx said NavDx has Medicare coverage and supports longitudinal disease management; the company expects Naveris’ revenue to grow 30% to 40% annually for the next three years. Naveris operates high-complexity clinical laboratories in Massachusetts and North Carolina and reported $34 million in unaudited 2025 revenue. Management emphasized the transaction is a targeted add-on within HPV-mediated oncology workflows rather than a broader move into MRD testing.
-
M&A dealmaking heats up in KRAS and immunology: AbbVie options Kestrel for pan-RAS inhibitor
AbbVie signed an agreement to acquire Kestrel Therapeutics under an option structure valued at up to $1.45 billion, contingent on milestones tied to Kestrel’s oral pan-KRAS inhibitor KST-6051. The deal follows Kestrel’s report that dosing began in a Phase 1 trial in KRAS-driven solid tumors. AbbVie’s oncology leadership said the collaboration aims to explore broader KRAS mutations, distinguishing the approach from therapies historically focused on narrower KRAS subsets. The agreement includes funding for development of the KST-6051 program, though the reporting did not detail specific development or regulatory triggers. As companies race to build next-generation KRAS pipelines, the structure signals that AbbVie is trying to buy optionality early rather than relying only on internal discovery.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.